TITLE

Makena Cuts Risk of Preterm Birth

PUB. DATE
February 2011
SOURCE
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p54
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of K-V Pharmaceutical Co.'s Makena (hydroxyprogesterone caproate injection) by the U.S. Food and Drug Administration (FDA), for the treatment to reduce the risk of preterm birth in women with singleton pregnancy.
ACCESSION #
59994632

 

Related Articles

  • Drug Pricing Lessons in the Aftermath of Makena's Approval. Thiel, Karl // BioWorld Today;5/3/2011, Vol. 22 Issue 85, p1 

    The article discusses the pricing issue arising from the U.S. Food and Drug Administration's (FDA) approval of K-V Pharmaceutical Co.'s drug Makena, a hydroxyprogesterone caproate for preventing premature labor. K-V priced Makena at 1,500 dollars per shot in the alleged hope that the FDA's...

  • Pharma: Other News To Note.  // BioWorld Today;7/3/2012, Vol. 23 Issue 128, p10 

    This section offers news briefs on pharmaceutical industry including the statement by K-V Pharmaceutical Co. that the U.S. Food and Drug Administration (FDA) has provided further guidance to health care providers and pregnant women at high risk for recurrent pre term birth and Janssen Research...

  • No major safety concerns with compounded hydroxyprogesterone.  // Reactions Weekly;6/23/2012, Issue 1407, p3 

    The article reports on the confirmation by the U.S. Food and Drug Administration (FDA) that its analysis of a limited sample of compounded hydroxyprogesterone products and active pharmaceutical ingredients (APIs) did not identify any major safety problems.

  • Economic Discretion.  // BioWorld Today;5/24/2013, Vol. 24 Issue 100, p6 

    The article reports that the U.S. Food and Drug Administration (FDA) has not enforced rules on drug compounders consistently due to concern that removing unsafe products out of the market may lead to higher costs of drugs. It cites the case when the FDA, due to congressional/public pressure on...

  • K-V Sues FDA.  // BioWorld Today;7/13/2012, Vol. 23 Issue 135, p5 

    The article reports on the lawsuit filed by K-V Pharmaceuticals Inc. against the U.S. Food and Drug Administration (FDA) over its alleged lack of enforcement of the company's seven-year orphan drug exclusivity for Makena due to pricing concerns for the helps in the prevention of premature births.

  • Judge reinstates suit based on FDA inspectional data. McCarty, Mark // Medical Device Daily;6/6/2012, Vol. 16 Issue 107, p1 

    The article focuses on a court decision allowing a lawsuit against KV Pharmaceuticals to proceed as a class action. The lawsuit alleges securities fraud against the company based on inspectional data from the U.S. Food and Drug Administration. Some observers are of the view that the court erred,...

  • FDA ROUNDUP.  // MondayMorning;7/9/2012, Vol. 20 Issue 27, p1 

    The article offers news briefs related to the U.S. Food & Drug Administration (FDA) in 2012. The agency approved a generic version of Pfizer's Lyrica nerve pain drug from Mumbai, India-based Lupin Ltd. Roche Holding AG obtained clearance for its DNA test to monitor the development of a treatment...

  • FDA actions. Elliott, William T. // Infectious Disease Alert;Apr2011 Pharmacology Watch, p2 

    The article focuses on several drug actions of the U.S. Food and Drug Administration (FDA). These include a warning issued against using terbutaline for prolonged treatment or prevention of preterm labor among pregnant women and the drug safety alert issued on the risk of serious liver injury in...

  • FDA actions. Elliott, William T. // Neurology Alert;Apr2011 Clinical Bri, p2 

    This section offers news briefs on actions taken by the U.S. Food and Drug Administration (FDA) as of April 2011. The hydroxyprogesterone caporate injection has gained FDA approval to reduce the risk of preterm delivery before 37 weeks of pregnancy in a pregnant woman with a history of at least...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics